{
  "pmcid": "5373818",
  "sha256": "1e1b18afe7aad5817b91c324c0db8ba2c5706582943b482131b45ea3908cbe73",
  "timestamp_utc": "2025-11-09T23:57:28.138915+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.477114427860702,
    "reading_ease": 17.787703150912137,
    "word_count": 268
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Anticoagulation Strategies in HIT-Positive Patients Undergoing Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either tirofiban with heparin or standard anticoagulation."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were adults with HIT requiring CPB."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either tirofiban with heparin or standard anticoagulation."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the efficacy and safety of tirofiban combined with heparin as an alternative anticoagulation strategy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of thrombotic events during and after surgery, assessed over a 30-day period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Due to the nature of the intervention, blinding was not feasible."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 50 participants were randomised: 25 to the tirofiban with heparin group and 25 to the control group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on an intention-to-treat basis."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The tirofiban group demonstrated a reduced incidence of thrombotic events (12% vs. 28%, p=0.04), with a mean difference of 16% (95% CI 2% to 30%)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Bleeding complications were observed in 16% of the tirofiban group and 20% of the control group, with no significant difference in severity."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: This study was funded by the National Institutes of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}